Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
fda
2
×
life sciences
2
×
national blog main
san diego blog main
san diego top stories
biotech
biotech ipos
blueprint medicines
boston
boulder/denver blog main
boulder/denver top stories
cancer
companion diagnostic
detroit blog main
detroit top stories
dna sequencing
drugs
dyne therapeutics
entrectinib
express scripts
foundation medicine
indiana blog main
indiana top stories
josh bilenker
keytruda
larotrectinib
loxo oncology
melanie nallicheri
merck
metacrine
myotonic dystrophy type 1
national
national top stories
new england journal of medicine
new york blog main
new york top stories
nonalcoholic steatohepatitis
What
drug
genetic
2
×
approved
brings
cancer
company
deeper
developing
disorders
dna
dyne
dyne’s
fda
fingerprint
going
ipo
matter
medicine
medicines
million
muscle
muscular
nd
new
oks
preclinical
raised
rare
second
stage
targets
therapeutics
time
tissues
topped
tumor's
upsized
world
Language
unset
Current search:
genetic
×
fda
×
" life sciences "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
